Cytokinetics Historical Financial Ratios
| CYTK Stock | USD 50.25 1.15 2.34% |
Cytokinetics is presently reporting on over 114 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 59.08 or Invested Capital of 0.0 will help investors to properly organize and evaluate Cytokinetics financial condition quickly.
Cytokinetics |
About Cytokinetics Financial Ratios Analysis
CytokineticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cytokinetics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cytokinetics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cytokinetics history.
Cytokinetics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cytokinetics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cytokinetics sales, a figure that is much harder to manipulate than other Cytokinetics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Cytokinetics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Capex To Revenue is quite stable compared to the past year. Income Quality is expected to rise to 0.95 this year, although Book Value Per Share will most likely fall to (4.20).
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 15.0 | 11.01 | 22.16 | 21.05 | Receivables Turnover | 1.36 | 643.46 | 5.87 | 5.58 |
Cytokinetics fundamentals Correlations
Click cells to compare fundamentals
Cytokinetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytokinetics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 22.74 | 24.02 | 49.76 | 43.51 | 1.1K | 1.1K | |
| Ptb Ratio | (55.85) | 11.83 | 14.37 | (38.14) | (20.86) | (19.82) | |
| Days Sales Outstanding | 70.14 | 28.9 | 268.56 | 0.57 | 62.19 | 59.08 | |
| Book Value Per Share | (0.19) | 1.76 | 3.17 | (1.2) | (4.0) | (4.2) | |
| Free Cash Flow Yield | (0.15) | (0.001573) | (0.0546) | (0.0755) | (0.0516) | (0.0542) | |
| Operating Cash Flow Per Share | (1.86) | (1.58) | 0.14 | (3.33) | (4.29) | (4.51) | |
| Stock Based Compensation To Revenue | 0.4 | 0.32 | 0.38 | 0.51 | 9.57 | 10.05 | |
| Capex To Depreciation | 2.03 | 6.04 | 21.47 | 1.95 | 0.12 | 0.11 | |
| Pb Ratio | (55.85) | 11.83 | 14.37 | (38.14) | (20.86) | (19.82) | |
| Ev To Sales | 26.44 | 25.02 | 51.99 | 50.74 | 1.2K | 1.2K | |
| Free Cash Flow Per Share | (1.62) | (0.0327) | (2.49) | (3.46) | (4.31) | (4.52) | |
| Payables Turnover | 10.55 | 12.04 | 7.58 | 9.4 | 15.35 | 17.69 | |
| Sales General And Administrative To Revenue | 1.47 | 0.95 | 1.37 | 1.88 | 23.06 | 24.21 | |
| Research And Ddevelopement To Revenue | 3.21 | 1.74 | 2.27 | 0.0696 | 0.0801 | 0.0761 | |
| Capex To Revenue | 0.0975 | 0.2 | 0.69 | 0.12 | 0.19 | 0.25 | |
| Pocfratio | (6.72) | 149.93 | (24.59) | (13.74) | (19.45) | (18.48) | |
| Interest Coverage | (3.61) | (2.43) | (6.35) | (6.34) | (8.6) | (9.03) | |
| Capex To Operating Cash Flow | (0.0288) | 1.24 | (0.34) | (0.0378) | (0.003418) | (0.003588) | |
| Pfcf Ratio | (6.53) | (635.76) | (18.31) | (13.24) | (19.38) | (20.35) | |
| Days Payables Outstanding | 34.58 | 30.31 | 48.12 | 38.82 | 23.78 | 21.11 | |
| Roe | (4.1) | 13.63 | (1.45) | 3.73 | 1.36 | 1.43 | |
| Ev To Operating Cash Flow | (7.82) | 156.18 | (25.69) | (16.02) | (21.0) | (19.95) | |
| Pe Ratio | (4.1) | (8.17) | (14.46) | (10.22) | (15.31) | (14.55) | |
| Return On Tangible Assets | (0.51) | (0.31) | (0.29) | (0.4) | (0.64) | (0.67) | |
| Ev To Free Cash Flow | (7.6) | (662.29) | (19.13) | (15.44) | (20.93) | (21.98) | |
| Earnings Yield | (0.24) | (0.12) | (0.0692) | (0.0978) | (0.0653) | (0.0686) | |
| Net Debt To E B I T D A | (1.07) | (0.64) | (0.89) | (2.08) | (1.41) | (1.34) | |
| Current Ratio | 8.98 | 15.2 | 7.45 | 9.4 | 6.12 | 5.78 | |
| Tangible Book Value Per Share | (0.19) | 1.76 | 3.17 | (1.2) | (4.0) | (4.2) | |
| Receivables Turnover | 5.2 | 12.63 | 1.36 | 643.46 | 5.87 | 5.58 | |
| Graham Number | 3.33 | 10.03 | 15.0 | 11.01 | 22.16 | 21.05 | |
| Shareholders Equity Per Share | (0.19) | 1.76 | 3.17 | (1.2) | (4.0) | (4.2) | |
| Debt To Equity | (12.24) | 1.22 | 0.65 | (5.77) | (1.64) | (1.73) | |
| Capex Per Share | 0.0455 | 0.17 | 0.64 | 0.13 | 0.0147 | 0.0139 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.